Poseida & Astellas/Xyphos enter allogeneic CAR-T collaboration; $50M upfront, $550M milestones

Poseida Therapeutics, Inc.

$50M upfront payment ($6M advanced for R&D); up to $550M in development/sales milestones plus low double-digit tiered royalties.
Two allogeneic convertible CAR-T candidates targeting solid tumors combining Poseida’s platform with Xyphos’ ACCEL technology.
Xyphos responsible for development/commercialization; Poseida performs research through IND-enabling data package.
Expands existing relationship; Astellas made strategic investment in Poseida in August 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Poseida Therapeutics, Inc. entered into Collaboration Agreement with Xyphos Biosciences, Inc. valued at $50.0 million (effective 2024-04-30).

Action: entry
Agreement: collaboration
Counterparty: Xyphos Biosciences, Inc.
Value: $50.0 million
Effective: 2024-04-30

Exact text from the filing

On April 30, 2024, Poseida Therapeutics, Inc. (the “Company”) and Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (“Xyphos”), entered into a collaboration and license agreement (the “Collaboration Agreement”),

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-126509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.